Recombinant p21 antibody (AA 1-100)

Catalog No. ABIN7504137

Product Details anti-p21 Antibody

Target: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Antibody Type: Recombinant Antibody

Binding Specificity: AA 1-100

Reactivity: Synthetic

Host: Rabbit

Clonality: Monoclonal

Conjugate: This p21 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Formalin-fixed Sections) (IHC (f))

Specificity: This MAb recognizes a 21 kDa protein, identified as the p21WAF1 tumor suppressor protein. This MAb is highly specific to p21 and shows no cross-reaction with other closely related mitotic inhibitors. p21WAF1 is a specific inhibitor of cdk s and a tumor suppressor involved in the pathogenesis of a variety of malignancies. The expression of this gene acts as an inhibitor of the cell cycle during G1 phase and is tightly controlled by the tumor suppressor protein p53. Its expression is induced by the wild type, but not mutant, p53 suppressor protein. Normal cells generally display a rather intense nuclear p21 expression. Loss of p21 expression has been reported in many carcinomas (gastric carcinoma, non-small cell lung carcinoma, thyroid carcinoma).

Cross-Reactivity (Details): Human.

Purification: 200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G.

Immunogen: Synthetic peptide corresponding to p21 residues within aa1-100 of p21 was used as an immunogen.

Isotype: IgG

Application Details

Application Notes:

Positive Control: HeLa cells. Human skin, colon, or breast carcinoma.

Known Application: Western Blot (2-4 μg/mL), ,Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT),(Staining of formalin-fixed tissues requires heating tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 min at 95 °C followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined.

Restrictions: For Research Use only

Handling

Concentration: 200 μg/mL

Buffer: Prepared in 10 mM PBS with 0.05 % BSA and 0.05 % azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-80 °C

Storage Comment: Antibody with azide - store at 2 to 8 °C. Antibody is stable for 24 months. Non-hazardous. Also available WITHOUT BSA & azide at 1.0mg/ml.

Expiry Date: 24 months

Target Details for p21

Target: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Alternative Name: CDKN1A (CDKN1A Products)

Synonyms: CCND1 antibody, CDKN1A antibody, CAP20 antibody, CDKN1 antibody, CIP1 antibody, MDA-6 antibody, P21 antibody, SDI1 antibody, WAF1 antibody, p21CIP1 antibody, CDKI antibody, Cdkn1 antibody, Waf1 antibody, mda6 antibody, p21Cip1 antibody, p21WAF antibody, Cip1 antibody, UV96 antibody, p21 antibody, cip1 antibody, p16Xic2 antibody, sdi1 antibody, waf1 antibody, cap20 antibody, cdkn1 antibody, mda-6 antibody, p21cip1 antibody, si:ch1073-48m5.2 antibody, KRAS2 antibody, p21ras antibody, cyclin D1 antibody, cyclin dependent kinase inhibitor 1A antibody, cyclin-dependent kinase inhibitor 1A (P21) antibody, cyclin-dependent kinase inhibitor 1A antibody, cyclin-dependent kinase inhibitor 1A L homeolog antibody, cyclin-dependent kinase inhibitor 1 antibody, KRAS proto-oncogene, GTPase antibody, CCND1 antibody, CDKN1A antibody, Cdkn1a antibody, cdkn1a.L antibody, cki1 antibody, cdkn1a antibody, KRAS antibody

Background: Activating Fragment 1, CAP20, CDK-interacting protein 1, CDKI, CDKN1, CDKN1A, CIP1, Cyclin-dependent kinase inhibitor 1A (p21, Cip1), DNA Synthesis Inhibitor, MDA6, Melanoma Differentiation Associated Protein 6, PIC1, SDI1, SLC12A9, p21Cip1/Waf1, Wild type p53 activated fragment 1 (WAF1),p21WAF1 (Tumor Suppressor Protein)
Cellular localisation: Nuclear

Molecular Weight: 21kDa

Gene ID: 1026, 370771

UniProt: P38936

Pathways: p53 Signaling, PI3K-Akt Signaling, Cell Division Cycle, AMPK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Mitotic G1-G1/S Phases, DNA Replication, Hepatitis C, Synthesis of DNA, Autophagy